– USA, MA – Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company, today announced the appointment of Richard Brudnick to its Board as an independent director.
“We are pleased to welcome Richard to Scholar Rock’s Board of Directors. Richard brings extensive corporate development experience and leadership acumen, having held several executive positions and currently serving as Chief Business Officer of Prime Medicine, which will be instrumental as Scholar Rock advances towards becoming a fully integrated biopharmaceutical company. As Scholar Rock’s deep pipeline continues to advance, the board and executive leadership team will benefit from Richard’s decades of broad experience in corporate development and strategy,” said Board chairman, David Hallal.
About Richard Brudnick
Mr. Brudnick is an accomplished biotechnology executive with over three decades of industry experience specializing in the corporate development of companies spanning multiple specialties, stages, and therapeutic areas.
“Scholar Rock has an impressive pipeline with the potential to meaningfully improve the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders and cancer,” said Mr. Brudnick. “I am excited to join the company’s Board of Directors, and I look forward to working with the other board members and the leadership team at this pivotal stage.”
Mr. Brudnick joined Prime Medicine as CBO in July 2022 and is responsible for corporate development and strategy. Before Prime, he served as CBO and Head of Strategy of Codiak BioSciences, a leader in the field of exosome therapeutics. Before joining Codiak, Mr. Brudnick served as EVP of Business Development and Alliance Management at Bioverativ. He led business development efforts to build a significant pipeline in rare blood disorders. Earlier, Mr. Brudnick spent nearly 15 years at Biogen. He initiated, led, and completed transactions that led to several marketed products including Leqembi, Tecfidera, Spinraza, and its biosimilars joint venture with Samsung.
Mr. Brudnick holds an M.S. and B.S. in Management Science from Massachusetts Institute of Technology Sloan School of Management. He also serves as a director of InflaRx and Tamarix Pharma.
About Scholar Rock
Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of severe diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. Scholar Rock’s approach to targeting the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path.
Source: https://scholarrock.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
